Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A common TMPRSS2 variant protects against severe COVID-19

Alessia David, Nicholas Parkinson, Thomas P Peacock, Erola Pairo-Castineira, Tarun Khanna, Aurelie Cobat, Albert Tenesa, Vanessa Sancho-Shimizu, GenOMICC Investigators, ISARIC4C Investigators, Jean-Laurent Casanova, Laurent Abel, Wendy S. Barclay, J. Kenneth Baillie, Michael JE Sternberg
doi: https://doi.org/10.1101/2021.03.04.21252931
Alessia David
1Centre for Integrative System Biology and Bioinformatics, Department of Life Sciences, Imperial College London, London, SW7 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alessia.david09@imperial.ac.uk
Nicholas Parkinson
2Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas P Peacock
3Department of Infectious Diseases, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erola Pairo-Castineira
2Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tarun Khanna
1Centre for Integrative System Biology and Bioinformatics, Department of Life Sciences, Imperial College London, London, SW7 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurelie Cobat
4St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
5Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France, EU
6University of Paris, Imagine Institute, Paris, France, EU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Tenesa
2Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Sancho-Shimizu
7Department of Paediatric Infectious Diseases & Virology, Imperial College London, London, UK
8Centre for Paediatrics and Child Health, Faculty of Medicine, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Laurent Casanova
4St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
5Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France, EU
6University of Paris, Imagine Institute, Paris, France, EU
9Howard Hughes Medical Institute, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Abel
4St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
5Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France, EU
6University of Paris, Imagine Institute, Paris, France, EU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy S. Barclay
3Department of Infectious Diseases, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Kenneth Baillie
2Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
10Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael JE Sternberg
1Centre for Integrative System Biology and Bioinformatics, Department of Life Sciences, Imperial College London, London, SW7 2BU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Infection with SARS-CoV-2 has a wide range of clinical presentations, from asymptomatic to life-threatening. Old age is the strongest factor associated with increased COVID19-related mortality, followed by sex and pre-existing conditions. The importance of genetic and immunological factors on COVID19 outcome is also starting to emerge, as demonstrated by population studies and the discovery of damaging variants in genes controlling type I IFN immunity and of autoantibodies that neutralize type I IFNs. The human protein transmembrane protease serine type 2 (TMPRSS2) plays a key role in SARS-CoV-2 infection, as it is required to activate the virus’ spike protein, facilitating entry into target cells. We focused on the only common TMPRSS2 non-synonymous variant predicted to be damaging (rs12329760), which has a minor allele frequency of ∼25% in the population. In a large population of SARS-CoV-2 positive patients, we show that this variant is associated with a reduced likelihood of developing severe COVID19 (OR 0.87, 95%CI:0.79-0.97, p=0.01). This association was stronger in homozygous individuals when compared to the general population (OR 0.65, 95%CI:0.50-0.84, p=1.3×10−3). We demonstrate in vitro that this variant, which causes the amino acid substitution valine to methionine, impacts the catalytic activity of TMPRSS2 and is less able to support SARS-CoV-2 spike-mediated entry into cells.

TMPRSS2 rs12329760 is a common variant associated with a significantly decreased risk of severe COVID19. Further studies are needed to assess the expression of the TMPRSS2 across different age groups. Moreover, our results identify TMPRSS2 as a promising drug target, with a potential role for camostat mesilate, a drug approved for the treatment of chronic pancreatitis and postoperative reflux esophagitis, in the treatment of COVID19. Clinical trials are needed to confirm this.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

AD and NP were supported by the Wellcome Trust (grants 104955/Z/14/Z and 211496/Z/18/Z) and TK by the BBSRC (grants BB/P011705/1 and BB/P023959/1), VSS is supported by UKRI Future Leader Fellowship (MR/S032304/1), TPP and WSB are supported by BBSRC grants BB/R013071/1, AT was supported by Roslin Institute Strategic Programme Grants from the BBSRC (BBS/E/D/10002070 and BBS/E/D/30002275) and Health Data Research UK (references HDR-9004 and HDR-9003).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Research ethics committees (Scotland 15/SS/0110, England, Wales and Northern Ireland: 19/WM/0247). Current and previous versions of the study protocol are available at genomicc.org/protocol. All participants gave informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Full summary-level data in support of the findings of this study are available for download from [https://genomicc.org/data](https://genomicc.org/data). Individual level data can be analysed by qualified researchers in the ISARIC 4C/GenOMICC data analysis platform by application at [https://genomicc.org/data] (https://genomicc.org/data). BioBank data and Genomics England data are available to registered researchers at https://www.ukbiobank.ac.uk/ and https://www.genomicsengland.co.uk/. The COVID19 Host Genetics Initiative2 (COVID19hg) summary statistics are available at https://www.covid19hg.org/.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted March 08, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A common TMPRSS2 variant protects against severe COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A common TMPRSS2 variant protects against severe COVID-19
Alessia David, Nicholas Parkinson, Thomas P Peacock, Erola Pairo-Castineira, Tarun Khanna, Aurelie Cobat, Albert Tenesa, Vanessa Sancho-Shimizu, GenOMICC Investigators, ISARIC4C Investigators, Jean-Laurent Casanova, Laurent Abel, Wendy S. Barclay, J. Kenneth Baillie, Michael JE Sternberg
medRxiv 2021.03.04.21252931; doi: https://doi.org/10.1101/2021.03.04.21252931
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A common TMPRSS2 variant protects against severe COVID-19
Alessia David, Nicholas Parkinson, Thomas P Peacock, Erola Pairo-Castineira, Tarun Khanna, Aurelie Cobat, Albert Tenesa, Vanessa Sancho-Shimizu, GenOMICC Investigators, ISARIC4C Investigators, Jean-Laurent Casanova, Laurent Abel, Wendy S. Barclay, J. Kenneth Baillie, Michael JE Sternberg
medRxiv 2021.03.04.21252931; doi: https://doi.org/10.1101/2021.03.04.21252931

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9757)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2303)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1553)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11631)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2139)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2172)
  • Public and Global Health (4645)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)